{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:14:35Z","timestamp":1792095275738,"version":"4.4.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2013,11,27]],"date-time":"2013-11-27T00:00:00Z","timestamp":1385510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Chronic hepatitis C (CHC)\u2013related cirrhosis is the leading indication for liver transplantation (LT). However, the recurrence of a hepatitis C virus (HCV) infection after transplantation is universal and is associated with worse outcomes. Fibrosing cholestatic hepatitis (FCH) is a particularly severe manifestation of a recurrent HCV infection and frequently results in graft failure and death. The identification of risk factors for FCH is important but has been limited by the low frequency of FCH. The interleukin-28B (<jats:italic toggle=\"yes\">IL-28B<\/jats:italic>) genotype is important in an HCV infection: it is related to the clinical severity of an acute infection and may play a role in the development of FCH as well. Two hundred seventy-two consecutive LT cases for CHC were studied at a single institution. Consensus criteria were used to define an FCH cohort. The remainder of the study population served as a control group. The <jats:italic toggle=\"yes\">IL-28B<\/jats:italic> genotype (at the rs12979860 locus) from both the donor and the recipient was determined, and other clinically relevant data were tabulated. A nonparametric statistical analysis was performed. Twelve cases of FCH were identified, and they were compared to a control group of 260 LT cases without FCH. A detailed analysis of clinical characteristics, including treatment responses and outcomes, was tabulated. FCH was associated with the earlier recurrence of HCV infections, higher HCV viral loads, and lower levels of immunosuppressive medications. There was a nonsignificant increase in recipient <jats:italic toggle=\"yes\">IL-28B<\/jats:italic> non-CC genotypes in cases developing FCH. In conclusion, a high HCV viral load and earlier recurrence were identified as risk factors for FCH. It is still unclear what role immunosuppression plays in the pathogenesis of FCH and whether <jats:italic toggle=\"yes\">IL-28B<\/jats:italic> polymorphisms constitute a risk factor. Collaborative studies with larger numbers of study subjects are needed in order to define these issues. <jats:italic toggle=\"yes\">Liver Transpl 19:1311-1317, 2013<\/jats:italic>. \u00a9 2013 AASLD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/lt.23733","type":"journal-article","created":{"date-parts":[[2013,8,27]],"date-time":"2013-08-27T15:22:38Z","timestamp":1377616958000},"page":"1311-1317","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Interleukin-28B and fibrosing cholestatic hepatitis in posttransplant hepatitis C: A case-control study and literature review"],"prefix":"10.1097","volume":"19","author":[{"given":"Andres","family":"Duarte-Rojo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Budhraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart J.","family":"Veldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kymberly D.","family":"Watt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie K.","family":"Heimbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"McHutchison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans L.","family":"Tillman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Poterucha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Charlton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-5-20250124","doi-asserted-by":"crossref","first-page":"328339","DOI":"10.1111\/j.1872-034X.2011.00781.x","article-title":"Clinical characterization of patients developing histologicallyproven fibrosing cholestatic hepatitis C postliver transplantation.","volume":"41","author":"Satapathy","year":"2011","journal-title":"Hepatol Res"},{"key":"R3-5-20250124","doi-asserted-by":"crossref","first-page":"905908","DOI":"10.1016\/j.transproceed.2011.02.034","article-title":"Successful treatment of fibrosing cholestatic hepatitis after liver transplantation.","volume":"43","author":"Cimsit","year":"2011","journal-title":"Transplant Proc"},{"key":"R4-5-20250124","doi-asserted-by":"crossref","first-page":"12281235","DOI":"10.1002\/lt.22175","article-title":"Postliver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria.","volume":"16","author":"Narang","year":"2010","journal-title":"Liver Transpl"},{"key":"R5-5-20250124","doi-asserted-by":"crossref","first-page":"399401","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatmentinduced viral clearance.","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"R6-5-20250124","doi-asserted-by":"crossref","first-page":"798801","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"key":"R7-5-20250124","first-page":"4958","article-title":"Interleukin28B polymorphism in hepatitis C and liver transplantation.","volume":"19","author":"DuarteRojo","year":"2013","journal-title":"Liver Transpl"},{"key":"R8-5-20250124","doi-asserted-by":"crossref","first-page":"671679","DOI":"10.1002\/lt.23402","article-title":"Early viral load and recipient interleukin28B rs12979860 genotype are predictors of the progression of hepatitis C after liver transplantation.","volume":"18","author":"Graziadei","year":"2012","journal-title":"Liver Transpl"},{"key":"R9-5-20250124","doi-asserted-by":"crossref","first-page":"E335E336","DOI":"10.1111\/j.1399-0012.2012.01678.x","article-title":"Interleukin28B polymorphisms are associated with fibrosing cholestatic hepatitis in recurrent hepatitis C after liver transplantation.","volume":"26","author":"Hanouneh","year":"2012","journal-title":"Clin Transplant"},{"key":"R10-5-20250124","first-page":"197203","article-title":"The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables.","volume":"94","author":"DuarteRojo","year":"2012","journal-title":"Transplantation"},{"key":"R12-5-20250124","doi-asserted-by":"crossref","first-page":"219226","DOI":"10.1002\/lt.21011","article-title":"Early histologic changes in fibrosing cholestatic hepatitis C.","volume":"13","author":"Dixon","year":"2007","journal-title":"Liver Transpl"},{"key":"R13-5-20250124","first-page":"396402","article-title":"Fibrosing cholestatic hepatitis: clinicopathologic spectrum, diagnosis and pathogenesis.","volume":"1","author":"Xiao","year":"2008","journal-title":"Int J Clin Exp Pathol"},{"key":"R14-5-20250124","doi-asserted-by":"crossref","first-page":"12141221","DOI":"10.1097\/TP.0b013e3181bd783c","article-title":"Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and longterm outcome.","volume":"88","author":"Selzner","year":"2009","journal-title":"Transplantation"},{"key":"R15-5-20250124","doi-asserted-by":"crossref","first-page":"24262433","DOI":"10.1111\/j.1600-6143.2008.02362.x","article-title":"Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection.","volume":"8","author":"Veldt","year":"2008","journal-title":"Am J Transplant"},{"key":"R16-5-20250124","doi-asserted-by":"crossref","first-page":"309311","DOI":"10.1002\/lt.21019","article-title":"Sustained resolution of fibrosing cholestatic hepatitis C despite viremic relapse after stopping pegylated interferon and ribavirin therapy.","volume":"13","author":"Bolkhir","year":"2007","journal-title":"Liver Transpl"},{"key":"R17-5-20250124","doi-asserted-by":"crossref","first-page":"14861487","DOI":"10.1097\/00007890-200105270-00023","article-title":"Interferon alpha 2B and ribavirin in severe recurrent cholestatic hepatitis C.","volume":"71","author":"Ong","year":"2001","journal-title":"Transplantation"},{"key":"R18-5-20250124","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1002\/lt.23516","article-title":"Efficacy of antiviral therapy for hepatitis C after liver transplantation with cyclosporine and tacrolimus: a systematic review and metaanalysis.","volume":"19","author":"Rabie","year":"2013","journal-title":"Liver Transpl"},{"key":"R19-5-20250124","doi-asserted-by":"crossref","first-page":"348353","DOI":"10.1053\/jlts.2003.50062","article-title":"Duration of antiviral therapy for cholestatic HCV recurrence may need to be indefinite.","volume":"9","author":"Gopal","year":"2003","journal-title":"Liver Transpl"},{"key":"R20-5-20250124","doi-asserted-by":"crossref","first-page":"12461253","DOI":"10.1002\/lt.21322","article-title":"Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study.","volume":"13","author":"McCashland","year":"2007","journal-title":"Liver Transpl"},{"key":"R21-5-20250124","doi-asserted-by":"crossref","first-page":"228235","DOI":"10.1053\/jlts.2003.50029","article-title":"Severe recurrent hepatitis C after liver retransplantation for hepatitis C virusrelated graft cirrhosis.","volume":"9","author":"Berenguer","year":"2003","journal-title":"Liver Transpl"},{"issue":"suppl 2","key":"R22-5-20250124","first-page":"S27S35","article-title":"Virology and pathogenesis of hepatitis C virus recurrence.","volume":"14","author":"Ramirez","year":"2008","journal-title":"Liver Transpl"},{"key":"R23-5-20250124","doi-asserted-by":"crossref","first-page":"104113","DOI":"10.1097\/PAS.0b013e31826a92ac","article-title":"The Hepatitis Aggressiveness Score (HAS): a novel classification system for postliver transplantation recurrent hepatitis C.","volume":"37","author":"Moreira","year":"2013","journal-title":"Am J Surg Pathol"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.23733","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.23733","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-201312000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T17:29:21Z","timestamp":1737739761000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-201312000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.23733","relation":{},"ISSN":["1527-6465"],"issn-type":[{"value":"1527-6465","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}